Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies

NCT04392102 is registered in ClinicalTrials.gov with Zai Lab (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT04392102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04392102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2020
Completion date
August 11, 2022
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer